At the heart of public health are physicians, who dedicate their lives to assuring that patients suffering from a myriad of disease states receive appropriate healthcare.
We at ViroPharma are in turn dedicated to physician education, and bringing new products to them.
Initially, on ViroPharma’s acquisition of Vancocin in 2004, rather than developing a sales organization to promote the drug we made the business decision to focus our attention on physician education and ensuring patient safety. Our objectives today are clear, and include assisting physicians in their work to assure the safety of, and appropriate therapies for, patients with severe C. difficile infections or hereditary angioedema (HAE).
Our focus will remain on physician education, but our broader ambitions also include developing new important drugs for other diseases, including those caused by C1 esterase inhibitor deficiency and recurrent CDI to improve the lives of patients.
Learn more about two of our therapeutic areas, gastroenterology and hospital/transplant medicine.